Edwards Lifesciences Corp (EW) · Nov 4, 2026 · Earnings
Beat — Adjusted EPS $0.80 vs ~$0.74 consensus
Edwards Lifesciences earnings beat consensus as TMTT surged 44%, prompting higher 2026 sales, TAVR and TMTT guidance.
Edwards is in the middle of shifting from a TAVR-led franchise toward a broader structural-heart portfolio, with mitral and tricuspid therapies becoming the faster-growing engine. Its prior Q2 update had already raised 2026 sales, TAVR and TMTT guidance, while keeping adjusted EPS at $2.95–$3.05.
The quarter cleared both the operating and earnings bar. Sales reached $1.716 billion versus a published consensus of about $1.68 billion, while adjusted EPS was $0.80 versus roughly $0.74 expected. The filing attributes the EPS upside to better top-line performance and planned phasing of R&D and SG&A spending.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Net sales (Financial Statements) | $1,715.5M | $1,553.1M | ~$1,680M consensus |
| Adjusted EPS (Non-GAAP reconciliation) | $0.80 | $0.67 | ~$0.74 consensus |
| TAVR growth (Outlook) | 9%–9.5% | — | 8%–9% prior guide |
| TMTT sales (Outlook) | $780M–$790M | — | $760M–$780M prior guide |
| Adjusted EPS (Outlook) | $2.97–$3.05 | — | $2.95–$3.05 prior guide |
The important business signal is the breadth of growth, not just the beat. TAVR grew 8.8% on a constant-currency basis, but TMTT grew 45.6%, with new PASCAL and EVOQUE approvals expanding the addressable mitral and tricuspid opportunity. The core TAVR franchise is also holding together: U.S. competitive position was stable sequentially and modestly higher year over year, while the updated CMS coverage policy and new Japanese reimbursement support access.
Management raised the full-year bar, but the quality of the raise is partly mix-driven. Total 2026 sales-growth guidance moved to approximately 11.5% from 10%–11%, TAVR growth rose to 9%–9.5% from 8%–9%, and TMTT guidance increased to $780M–$790M. 〔0〕 The company now expects future growth to rely more on procedure volumes and less on share gains, which makes the outlook healthier if those volume trends persist but less dependent on continued competitive wins.
The headline earnings strength should be read through the large special charges. GAAP operating income was pressured by a $220.2 million impairment charge tied to acquired in-process R&D and fixed assets, leaving GAAP diluted EPS at $0.53 versus adjusted EPS of $0.80. That charge does not negate the operating beat, but it shows that parts of the acquisition and investment portfolio are still being reset.
Bottom line: This was a genuinely better-than-expected quarter with a meaningful guidance lift, led by accelerating TMTT growth and improving procedure demand. The event strengthens Edwards’ broadening structural-heart story, although the GAAP impairment highlights lingering costs from past investments.
Q4 results and 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!